Visual acuity outcome in patients with diabetic maculopathy • JML Journal of Medicine and Life

2014, Volume 7, Issue Spec Iss 2, pp 71 – 75

Visual acuity outcome in patients with diabetic maculopathy

Issues

Special Issues

Authors and Affiliations

Serban R ^*

Cioboata M ^*

Chiotan C ^**

Cornăcel C ^*

Liora R ^*

Anghelie A ^*

* *Ophthalmology Emergency Hospital Bucharest

** **Department of HIV / AIDS, Office of Ophthalmology, ”Prof. Dr. Matei Bals” Institute of Infectious Diseases, Bucharest

Correspondence to:Serban Ramona, MD Ophthalmology Emergency Hospital Bucharest, Romania, 1 Alexandru Lahovari Market, District 1, Bucharest Mobile phone: 0721 299 637, E-mail: drserbanramona@yahoo.com

Abstract

The purpose of this study is to follow up visual acuity in patients diagnosed with clinically significant macular edema and treated by an intravitreal injection of triamcinolone acetonide or in combination with bevacizumab. The working method: based on the selectivity criteria we involved 295 patients (460 eyes), divided into 2 groups according to the treatment administered and one control group.

The results showed a better preservation of the functional parameter for the group of patients treated with intravitreal injection of triamcinolone acetonide and bevacizumab.

Abbreviations: VA = visual acuity, VA0 = visual acuity at study entry, WESDR = Wisconsin epidemiological study of diabetic retinopathy, ETDRS = Early treatment diabetic retinopathy study, OCT = optical coherence tomography

Keywords

Diabetic Maculopathyclinically significant macular edemaTriamcinolone acetonidebevacizumabVisual acuity

Preview

JMedLife-07-71

Download PDF

About this article

PMC ID: 4391359
PubMed ID: 25870678
DOI:

Article Publishing Date (print): 2014
Available Online:

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.